{
  "id": 810385,
  "title": "HeartBeam Q2 slides show clinical progress despite wider Q2 2026 loss",
  "url": "https://urgent.news/2026/08/13/heartbeam-q2-slides-show-clinical-progress-despite-wider-q2-2026-loss",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-13T22:00:01.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/heartbeam-q2-slides-show-clinical-progress-despite-wider-q2-2026-loss-93CH-4859447"
  },
  "original_language": "en",
  "account": "HeartBeam Inc. (NASDAQ:BEAT) released its second-quarter 2026 financial results on August 13, demonstrating clinical progress while reporting a much larger net loss than anticipated. The cardiac monitoring technology company's stock rose initially before sliding back after hours. HeartBeam is focusing on a portable 12-lead ECG platform aimed at a $40 billion cardiac monitoring market, with a particular emphasis on expanding indications for heart attack detection. Although the company showcased improved cash discipline and clinical momentum, the earnings per share of negative $1.10 significantly underperformed analyst expectations, which stood at negative $0.09 per share. The company's second-quarter financials revealed a net loss of $5.0 million, a decrease of 17% from the second quarter of the previous year and an improvement of 12% from the first quarter of 2026. However, excluding $0.9 million in one-time items, the underlying net loss was approximately $4.1 million. Chief Financial Officer Tim Cruickshank highlighted the company's focus on cost management, with operating cash flow decreasing by 7% from the first quarter to $3.3 million. The company expects full-year 2026 operating cash outflow to remain below $14.0 million, with the fourth quarter's cash flow projected to drop below $2.5 million per quarter. HeartBeam made substantial progress on its heart attack detection program, advancing multiple clinical studies ahead of schedule. The ALIGN-ACS pilot study completed enrollment in less than four months and will present results at the TCT 2026 conference in San Diego. Meanwhile, the HEADSTART-ACS pilot study surpassed 50% enrollment in under three months, evaluating the accuracy of HeartBeam's ECG technology in detecting heart attacks in real-world settings. The company has initiated a patch pilot study evaluating its 12-lead ECG patch in approximately 50 patients with high risk of coronary artery disease. HeartBeam submitted a pre-submission package to the FDA and plans to pursue a 510(k) regulatory pathway for its heart attack detection indication.",
  "summary": null,
  "key_points": [
    "HeartBeam reported a $5.0 million net loss in Q2 2026, down 17% from the previous year.",
    "CFO Tim Cruickshank emphasized cost management, with operating cash flow at $3.3 million in Q2."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}